fda tirzepatide compounding federal mandate Tirzepatide, FDA, and Compounding: Understanding the Current Landscape Tirzepatide / Niacinamide Injection The Impact of New FDA

While oral semaglutide has been available since 2019 as Rybelsus for type 2 diabetes , this marks the first time an oral pill in this drug class has been approved for chronic weight management

High Dose (7.2 mg Wegovy HD): Approved in March 2026, this version has shown a mean weight reduction of 20.7% in clinical trials, rivaling the results of bariatric surgery

Common early effects may include: Mild nausea Reduced appetite Digestive changes such as bloating Temporary fatigue Regular follow-up appointments help monitor weight trends, hydration levels and nutritional intake

Two research vials create two chances for contamination, a label error, or weak material